PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.95%
Negative EBIT growth while TRAW is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-95.43%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-134.36%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-134.21%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-134.21%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.82%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-141.82%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.42%
Negative 10Y OCF/share CAGR while TRAW stands at 77.68%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31.42%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-183.28%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1.36%
Below 50% of TRAW's 98.31%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1.36%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
-52.35%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.38%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Negative asset growth while TRAW invests at 81849.33%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-12.67%
We have a declining book value while TRAW shows 59775.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-28.84%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
60.35%
SG&A declining or stable vs. TRAW's 61301.60%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.